Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- PL Intelligence
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- PL Intelligence
- Overview
- Industry news
- Deals review
- Press releases
- Articles
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing
is a division of
is a division of
- Companies
- Company details
Rhein Biotech
Rhein Biotech GmbH - the Technology Centre of the Rhein Biotech Group - is dedicated to the development of recombinant gene expression and full process technologies for the production of proteins.The company in detail
Summary
Dynavax Europe was formed following the acquisition of Rhein Biotech GmbH by Dynavax Technologies in April 2006. The company develops, manufactures, licenses-out and markets biopharmaceutical products and technologies. Dynavax Europe has pursued a business model that combines development of proprietary biopharmaceutical products and establishing strategic alliances designed to leverage and add value to its core capabilities in the areas of process, analytical and preclinical development, quality control, quality assurance, manufacturing and technology transfer. Through marketing and sales of recombinant antigens on the diagnostic market, Dynavax Europe leverages the value of the established vaccine production technologies.
R&D
To view this information, you must subscribe to PL Intelligence.
Partnerships
To view this information, you must subscribe to PL Intelligence.
Deals
To view this information, you must subscribe to PL Intelligence.
© Copyright 1995-2009 Pharmalicensing, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us